LLY vs LULU: Which Is the Better Buy?
Side-by-side comparison of Eli Lilly and Company and Lululemon Athletica Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-05-04.
Eli Lilly and Company · Healthcare
$934.34
+98.6% upside to fair value
Grade B
High Quality
VS
Lululemon Athletica Inc. · Consumer Cyclical
$128.98
+307.7% upside to fair value
Grade C
QuantHub Verdict
LULU has more upside to fair value
(+307.7%).
LULU trades at a lower forward P/E
(9.7x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
LLY |
LULU |
| Current Price |
$934.34 |
$128.98 |
| Fair Value Estimate |
$1,855.91 |
$525.85 |
| Upside to Fair Value |
+98.6%
|
+307.7%
|
| Market Cap |
$882.8B |
$15.1B |
| Forward P/E |
33.1x
|
9.7x
|
| EV / EBITDA |
27.9x
|
5.6x
|
| Price / Sales |
12.2x
|
1.4x
|
| Price / FCF |
65.0x
|
16.4x
|
| Revenue Growth YoY |
+55.5%
|
+0.8%
|
| Gross Margin |
82.7%
|
56.6%
|
| Operating Margin |
46.3%
|
19.8%
|
| Return on Equity |
101.3%
|
34.8%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
1.54%
|
6.09%
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
Eli Lilly and Company is a leading global pharmaceutical firm with a dominant position in the diabetes and obesity markets, driven by its blockbuster GLP-1 drugs Mounjaro and Zepbound which generated $36.5 billion in FY2025. The company reported $65.2 billion in total revenue for 2025, making it the top pharma by revenue globally. It exhibits high business quality with a durable competitive moat …
Lululemon Athletica Inc. is a premium athletic apparel retailer operating primarily in the consumer cyclical sector with a focus on apparel retail. The company has a strong brand and historically high profitability with a gross margin of 56.6% and ROE of 34.8%, but it faces significant near-term challenges including earnings pressure with a 21.6% decline in earnings in the most recent quarter and…
Accumulation Zones
| Metric |
LLY |
LULU |
| Zone Low |
$1,391.93 |
$394.39 |
| Zone High |
$1,577.52 |
$446.97 |
| In Buy Zone? |
Yes
|
Yes
|